Niagen Bioscience (NASDAQ:NAGE) Coverage Initiated by Analysts at Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of Niagen Bioscience (NASDAQ:NAGE) in a research report sent to investors on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $13.00 price objective on the stock.

Niagen Bioscience Trading Up 7.3%

Shares of Niagen Bioscience stock opened at $10.60 on Tuesday. Niagen Bioscience has a 52 week low of $2.31 and a 52 week high of $11.06. The company has a market capitalization of $834.96 million, a PE ratio of 62.35 and a beta of 1.94. The business has a 50-day simple moving average of $7.94.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.